文献速递糖尿病

鼻内纳洛酮对易感个体低血糖相关自主神经衰竭的影响

Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究为随机双盲安慰剂对照交叉研究,纳入健康非糖尿病志愿者,通过高胰岛素低血糖钳夹(血糖最低值54 mg/dL)诱导低血糖相关自主神经衰竭(HAAF)。17名参与者中9名发生HAAF,证实个体易感性存在差异;在易感者中,纳洛酮维持了部分激素和症状反应,并防止了葡萄糖输注需求增加。作者认为鼻内纳洛酮可能改善HAAF的部分特征,需进一步研究。

要点

  • 17名健康志愿者中9名在3次低血糖后发生HAAF,显示个体易感性不同。
  • 在HAAF易感者中,纳洛酮维持了部分激素和症状反应,并防止了葡萄糖输注需求增加。
  • 纳洛酮意外降低了首次低血糖时的血浆肾上腺素和GH反应,但防止了后续低血糖时的进一步降低。

核心结论

  • 鼻内纳洛酮可能改善HAAF的部分特征,这是首个报告该效应的研究。
  • 需进一步研究HAAF个体易感性差异的机制及鼻内纳洛酮对有HAAF风险的糖尿病患者的效应。

研究设计与样本

  • 随机、双盲、安慰剂对照交叉研究,在学术研究中心进行。
  • 参与者为健康非糖尿病志愿者。
  • 采用配对2天研究,间隔5至10周,每天包含3次连续低血糖发作(高胰岛素低血糖钳夹,血糖最低值54 mg/dL):第1天2次发作时给予鼻内纳洛酮或安慰剂,第2天进行第3次发作。

主要发现

  • 17名参与者中9名发生HAAF,证实个体易感性存在差异。
  • 在HAAF易感者中,纳洛酮维持了部分激素和症状反应,并防止了相关的葡萄糖输注需求增加。
  • 纳洛酮意外降低了首次低血糖发作时的血浆肾上腺素和GH反应,但防止了后续低血糖时的进一步降低。

局限性

  • 需进一步研究HAAF个体易感性差异的机制及鼻内纳洛酮对有HAAF风险的糖尿病患者的效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hypoglycemia-associated autonomic failure (HAAF), defined as blunting of counterregulatory hormone and symptom responses to recurrent hypoglycemia, remains a therapeutic challenge in diabetes treatment. The opioid system may play a role in HAAF pathogenesis since activation of opioid receptors induces HAAF. Blockade of opioid receptors with intravenous naloxone ameliorates HAAF experimentally yet is not feasible therapeutically. OBJECTIVE: To investigate the effects of opioid receptor blockade with intranasal naloxone on experimentally induced HAAF. DESIGN: Randomized, double-blinded, placebo-controlled crossover study. SETTING: Academic research center. PARTICIPANTS: Healthy nondiabetic volunteers. INTERVENTIONS: Paired 2-day studies, 5 to 10 weeks apart, each consisting of 3 consecutive hypoglycemic episodes (hyperinsulinemic hypoglycemic clamps, glucose nadir: 54 mg/dL): 2 on day 1 with administration of intranasal naloxone vs placebo, followed by the third episode on day 2. MAIN OUTCOME MEASURES: Differences in counterregulatory hormones responses and hypoglycemia symptoms between first and third hypoglycemic episodes in naloxone vs placebo studies. RESULTS: Out of 17 participants, 9 developed HAAF, confirming variable interindividual susceptibility. Among participants susceptible to HAAF, naloxone maintained some hormonal and symptomatic responses to hypoglycemia and prevented the associated requirement for increased glucose infusion. Unexpectedly, naloxone reduced plasma epinephrine and GH responses to the first hypoglycemic episode but prevented further reduction with subsequent hypoglycemia. CONCLUSION: This is the first study to report that intranasal naloxone, a widely used opioid receptor antagonist, may ameliorate some features of HAAF. Further investigation is warranted into mechanisms of variable interindividual susceptibility to HAAF and the effects of intranasal naloxone in people with diabetes at risk for HAAF.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Aleksic S, Lontchi-Yimagou E, Mitchell W, et al. Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals. J Clin Endocrinol Metab. 2025. PMID: 39026458. doi:10.1210/clinem/dgae479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。